Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 9/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BAX | Q07812 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286263 | 0.92 | LTA4H (0.42) | ALDH1A1MAPK1LTA4HTSHRPLA2G2A | |
| SCHEMBL10739081 | 0.85 | ALDH1A1 (0.61) | ALDH1A1MAPK1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL314128 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LTA4HTSHRPLA2G2AGLA | |
| SCHEMBL20692333 | 0.77 | MAPK1 (0.37) | ALDH1A1MAPK1TSHRNR1H2CYP3A4 | |
| SCHEMBL29565879 | 0.76 | LTA4H (0.61) | ALDH1A1LTA4HPLA2G2AGLAGAA | |
| SCHEMBL11568945 | 0.74 | FFAR1 (0.53) | LTA4HTSHRGLAGAAHTT | |
| SCHEMBL30330899 | 0.74 | LTA4H (0.41) | ALDH1A1LTA4HTSHRPLA2G2AGLA | |
| SCHEMBL13969406 | 0.73 | LTA4H (0.55) | ALDH1A1LTA4HTSHRPLA2G2AHTT | |
| SCHEMBL10920643 | 0.73 | NPC1 (0.47) | ALDH1A1MAPK1TSHRRAB9ACYP1A2 | |
| SCHEMBL28167886 | 0.73 | KDM4E (0.46) | ALDH1A1TSHRHTTRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| US-7144917-B2 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006036928-A2 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | WAYNE STATE UNIVERSITY (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1309579-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES | UNIV WAYNE STATE (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | WAYNE STATE UNIVERSITY | 2004-07-01 | — | — | US | disclosed |
| US-6703415-B2 | EPOXIDES OR THIIRANE DERIVATIVES; TREATING OR PREVENTING CANCER, ANGIOGENESIS, ARTHRITIS, CONNECTIVE TISSUE DISEASE, CARDIOVASCULAR DISEASE, INFLAMMATION OR AUTOIMMUNE DISEASE; ANTIFERTILITY AGENTS | WAYNE STATE UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| EP-1309579-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | UNITED STATES GOVERNMENT SECRETARY OF THE ARMY, THE | 2002-03-28 | — | — | US | disclosed |
| WO-2001092244-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037916-A1 | Inhibitors of matrix metallaproteinases | MMP12, MMP1, MMP3 | ALDH1A1 1067/4885MAPK1 2265/4885LTA4H 718/4885 |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | ALDH1A1 288/4885MAPK1 656/4885LTA4H 486/4885 |
| US-20040127478-A1 | Inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | ALDH1A1 1774/4885MAPK1 1051/4885LTA4H 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.